Structure Therapeutics Inc.

Structure Therapeutics Inc.

$45.59
-1.16 (-2.48%)
NASDAQ
USD, US
Biotechnology

52 Week Range

25.57-75.017

Beta

-5.13

Market Cap

$2.13B

Last Dividend

0

PE (TTM)

-21.7

Dividend Yield (TTM)

0

Price Chart

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Raymond C. Stevens Ph.D.

Full-Time Employees

111

IPO Date

2023-02-03

Description

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Phone

628-229-9277

Address

611 Gateway Boulevard, South San Francisco, CA, 94080, US

CIK

0001888886